Synergistic neutralization of rubella virus by monoclonal antibodies to viral haemagglutinin. 1987

G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini

Using murine monoclonal antibodies (MAbs) to rubella virus haemagglutinin, five epitopes were identified in competitive ELISA binding assays: A, B, D and E by haemagglutination-inhibiting (HI) MAbs with no neutralizing (Nt) activity, and C by a MAb with neither activity. However, when HI and Nt activities were determined in the presence of anti-mouse immunoglobulins, epitopes A, B and D were defined by both HI and Nt MAbs, whereas epitopes C and E were identified by HI MAbs without Nt activity. A synergistic Nt activity, in the absence of anti-mouse immunoglobulins, was displayed by mixtures of antibodies of different epitope groups. Analysis of mixtures of MAb pairs each belonging to a different epitope class, showed that synergistic Nt activity was elicited primarily by the group A epitope, secondarily by groups B and D and only minimally by groups C and E.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006389 Hemagglutinins, Viral Specific hemagglutinin subtypes encoded by VIRUSES. Viral Hemagglutinin,Viral Hemagglutinins,Hemagglutinin, Viral
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral

Related Publications

G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
January 1986, Archives of virology,
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
January 1992, Archives of virology,
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
June 1994, Journal of virology,
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
March 1986, Journal of virology,
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
January 1997, Viral immunology,
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
January 2013, PLoS pathogens,
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
July 1981, Science (New York, N.Y.),
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
January 2011, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
July 1967, Nature,
G Gerna, and M G Revello, and M Dovis, and E Petruzzelli, and G Achilli, and E Percivalle, and M Torsellini
November 1981, Virology,
Copied contents to your clipboard!